Merck settled patent litigation with BMS and Ono Pharmaceutical over Keytruda (pembrolizumab) by paying $625M upfront plus ongoing royalties on worldwide Keytruda sales. The settlement resolved disputes over anti-PD-1 antibody intellectual property, enabling Merck to continue marketing Keytruda, which became the world's top-selling drug exceeding $25B in annual sales.